Clinical Study
Osteoporosis and Bisphosphonate-Related Osteonecrosis of the Jaw Bone
Table 1
Patients’ characteristics, osteonecrosis of the jaw and dental treatments.
| | Total | | (%) |
| Age category | | 50–60 | 14 (18.4) | 61–70 | 27 (35.5) | 71–79 | 28 (36.9) | 80+ | 7 (9.2) | Median (IQR) | 69 (62–74) |
| Smoking status | | Never | 56 (73.7) | Current | 9 (11.8) | Former | 11 (14.5) |
| Medical history | |
| Hypertension | | No | 50 (65.8) | Yes | 26 (34.2) |
| Cardiovascular disease | | No | 60 (78.9) | Yes | 16 (21.1) |
| Immunosuppressant | | No | 72 (94.7) | Yes | 4 (5.3) |
| Previous radio/chemotherapy | | No | 73 (96.1) | Yes | 3 (3.9) |
| BPs and BRONJ | |
| BPs treatment | | Alendronate | 47 (61.8) | Clodronate | 16 (21.1) | Ibandronate | 3 (3.9) | Risedronate | 10 (13.2) |
| ONJ at first visit | | No | 69 (90.8) | Yes | 7 (9.2) |
| ONJ Stage | | 0 | 57 (89.1) | I | 3 (4.7) | II | 4 (6.3) |
| ONJ Site | | Maxilla | 1 (14.3) | Jaw Bone | 6 (85.7) |
| Oral care | |
| Minor ONJ surgery | | No | 72 (94.7) | Yes | 4 (5.3) |
| Dental treatment | | No | 31 (40.8) | Yes | 45 (59.2) |
|
|
ONJ: Osteonecrosis of the jaw; BPs: Bisphosphonates.
|